Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
BACKGROUND: We compared ranibizumab--a recombinant, humanized, monoclonal antibody Fab that neutralizes all active forms of vascular endothelial growth factor A--with photodynamic therapy with verteporfin in the treatment of predominantly classic neovascular age-related macular degeneration. METHODS: During the first year of this 2-year, multicenter, double-blind study, we randomly assigned patients in a 1:1:1 ratio to receive monthly intravitreal injections of ranibizumab (0.3 mg or 0.5 mg) plus sham verteporfin therapy or monthly sham injections plus active verteporfin therapy. The primary end point was the proportion of patients losing fewer than 15 letters from baseline visual acuity at 12 months. RESULTS: Of the 423 patients enrolled, 94.3% of those given 0.3 mg of ranibizumab and 96.4% of those given 0.5 mg lost fewer than 15 letters, as compared with 64.3% of those in the verteporfin group (P<0.001 for each comparison). Visual acuity improved by 15 letters or more in 35.7% of the 0.3-mg group and 40.3% of the 0.5-mg group, as compared with 5.6% of the verteporfin group (P<0.001 for each comparison). Mean visual acuity increased by 8.5 letters in the 0.3-mg group and 11.3 letters in the 0.5-mg group, as compared with a decrease of 9.5 letters in the verteporfin group (P<0.001 for each comparison). Among 140 patients treated with 0.5 mg of ranibizumab, presumed endophthalmitis occurred in 2 patients (1.4%) and serious uveitis in 1 (0.7%). CONCLUSIONS: Ranibizumab was superior to verteporfin as intravitreal treatment of predominantly classic neovascular age-related macular degeneration, with low rates of serious ocular adverse events. Treatment improved visual acuity on average at 1 year. (ClinicalTrials.gov number, NCT00061594 [ClinicalTrials.gov].).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The MARINA and ANCHOR trials with ranibizumab showed an incidence of 0.05% [30, 31], and a subsequent comparison study of ranibizumab and bevacizumab for neovascular AMD reported rates of 0.16% for ranibizumab and 0.5% for bevacizumab [32].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“Ranibizumab anti-Fab immunoreactivity in treatment-naïve patients was between 0–0.9% in the MARINA and ANCHOR trials [30, 31].”
From Mechanisms of sterile inflammation after intravitreal injection of antiangiogenic drugs: a narrative review (2021) · cites this paper as [31]
In the citing paper
“However, the requirement for lifelong injections imposes a substantial burden on patients and caregivers, and many patients fail to maintain initial therapeutic benefits owing to noncompliance with the burdensome treatment regimen. 3 , 7 , 8 , 10 , 13 – 20”
From Design and Characterization of a Novel Intravitreal Dual-Transgene Genetic Medicine for Neovascular Retinopathies (2024) · cites this paper as [14]
In the citing paper
“In the ANCHOR and MARINA studies, 8-14% of eyes gained 415 letters during months 4 to 12. [22][23][24]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
In the citing paper
“It is now accepted that the best outcomes with anti-VEGF therapies in n-AMD are achieved with regular dosing at specific intervals, usually monthly, as demonstrated in the pivotal trials of ranibizumab, and sometimes two monthly in the first year with aflibercept after the ' three monthly initiation doses'.[22][23][24][25]”
From Defining response to anti-VEGF therapies in neovascular AMD (2015) · cites this paper as [23]
10 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Ranibizumab for Neovascular Age-Related Macular Degeneration
Rosenfeld, P. J., Brown, D. M., Heier, J. S., Boyer, D. S., Kaiser, P. K., Chung, C. Y., & Kim, R. Y. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054481 · Cited by 5,886
Self-citationA sharper Bonferroni procedure for multiple tests of significance
HOCHBERG, Y. (1988) · Biometrika · doi:10.1093/biomet/75.4.800 · Cited by 4,829
Global data on visual impairment in the year 2002.
(2004) · Europe PMC (PubMed Central) · Cited by 4,157
Some Methods for Strengthening the Common χ 2 Tests
Cochran, W. G. (1954) · Biometrics · doi:10.2307/3001616 · Cited by 3,718
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Prevalence of Age-Related Macular Degeneration in the United States
(2004) · Archives of Ophthalmology · doi:10.1001/archopht.122.4.564 · Cited by 2,736
Pegaptanib for neovascular age-related macular degeneration
Gragoudas, E. S., Adamis, A. P., Cunningham, E. T., Feinsod, M., & Guyer, D. R. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa042760 · Cited by 2,337
(1999) · Archives of Ophthalmology · doi:10.1001/archopht.117.10.1329 · Cited by 2,192
Age-Related Macular Degeneration and Blindness due to Neovascular Maculopathy
Ferris, F. L., Fine, S. L., & Hyman, L. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040031330019 · Cited by 1,093
Research works printed but not linked: 2
- Resnikoff S, 2004, Bull World Health Organ, 82, 844
- Bressler NM, 2001, Arch Ophthalmol, 119, 198
Cited by
Items 201–300 of 1,025
Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions
Lux, A., Llacer, H., Heussen, F. M. A., & Joussen, A. M. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2006.113902 · Cited by 168
Clinical update: new treatments for age-related macular degeneration
Wong, T. Y., Liew, G., & Mitchell, P. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61104-0 · Cited by 166
Cho, M., Barbazetto, I. A., & Freund, K. B. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.02.012 · Cited by 166
Querques, G., Srour, M., Massamba, N., Georges, A., Ben Moussa, N., Rafaeli, O., & Souied, E. H. (2013) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.13-11665 · Cited by 165
Berg, K., Hadzalic, E., Gjertsen, I., Forsaa, V., Berger, L. H., Kinge, B., Henschien, H., Fossen, K., Markovic, S., Pedersen, T. R., et al. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.018 · Cited by 162
Grisanti, S., & Tatar, O. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.05.002 · Cited by 165
“The proof of concept was delivered by clinical studies showing that intravitreal administration of a VEGF antagonist ameliorated the visual outcome as compared with sham injections (Gragoudas et al., 2004; Brown et al., 2006; Rosenfeld et al., 2006).”
ResultSustained Ocular Delivery of Fluocinolone Acetonide by an Intravitreal Insert
Campochiaro, P. A., Hafiz, G., Shah, S. M., Bloom, S., Brown, D. M., Busquets, M., Ciulla, T., Feiner, L., Sabates, N., Billman, K., et al. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.11.024 · Cited by 161
Self-citationAflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab
Cho, H., Shah, C. P., Weber, M., & Heier, J. S. (2013) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2013-303344 · Cited by 161
Self-citationWecker, T., Ehlken, C., Bühler, A., Lange, C., Agostini, H., Böhringer, D., & Stahl, A. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-308668 · Cited by 162
Differential roles of PDGFR‐α and PDGFR‐β in angiogenesis and vessel stability
Zhang, J., Cao, R., Zhang, Y., Jia, T., Cao, Y., & Wahlberg, E. (2009) · The FASEB Journal · doi:10.1096/fj.08-113860 · Cited by 162
Zhu, Q., Ziemssen, F., Henke‐Fahle, S., Tatar, O., Szurman, P., Aisenbrey, S., Schneiderhan‐Marra, N., Xu, X., & Grisanti, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.04.023 · Cited by 157
Ranibizumab for Neovascular Age-Related Macular Degeneration
Liew, G., & Mitchell, P. (2007) · New England Journal of Medicine · doi:10.1056/nejmc063011 · Cited by 157
Anderson, W. J., da Cruz, N. F. S., Lima, L. H., Emerson, G. G., Rodrigues, E. B., & Melo, G. B. (2021) · International Journal of Retina and Vitreous · doi:10.1186/s40942-021-00307-7 · Cited by 155
Heier, J. S., Boyer, D. S., Nguyen, Q. D., Marcus, D. M., Roth, D. B., Yancopoulos, G. D., Stahl, N., Ingerman, A., Vitti, R., Berliner, A. J., et al. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.03.020 · Cited by 156
“3 mg every month for 2 years in the pivotal phase 3 studies, Minimally Classic/Occult Trial of the AntiVEGF Antibody Ranibizumab in the Treatment of Neovascular Age-Related Macular Degeneration (MARINA) and Anti-VEGF Antibody for the Treatment of Predominantly Classic Choroidal Neovascularization in Age-Related Macula…”
BackgroundSelf-citationAnimal models of ocular angiogenesis: from development to pathologies
Liu, C., Wang, Z., Sun, Y., & Chen, J. (2017) · The FASEB Journal · doi:10.1096/fj.201700336r · Cited by 152
Cell-Based Therapy for Degenerative Retinal Disease
Zarbin, M. A. (2016) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2015.12.007 · Cited by 172
Vascular endothelial growth factor: Biology and therapeutic applications
Ho, Q. T., & Kuo, C. J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.04.010 · Cited by 182
Oubraham, H., Cohen, S. Y., Samimi, S., Marotte, D., Bouzaher, I., Bonicel, P., Fajnkuchen, F., & Tadayoni, R. (2011) · Retina · doi:10.1097/iae.0b013e3181de5609 · Cited by 151
Oishi, A., Kojima, H., Mandai, M., Honda, S., Matsuoka, T., Oh, H., Kita, M., Nagai, T., Fujihara, M., Bessho, N., et al. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.05.024 · Cited by 150
“Currently, the first-choice treatment of AMD is administration of anti–vascular endothelial growth factor (VEGF) agents such as ranibizumab, which was shown to have a vision-improving effect in pivotal trials.(6,7) Several reports demonstrated favorable results of anti-VEGF therapy such as bevacizumab or ranibizumab i…”
Ranibizumab (Lucentis) versus bevacizumab (Avastin): modelling cost effectiveness
Raftery, J., Clegg, A., Jones, J., Tan, S. C., & Lotery, A. (2007) · British Journal of Ophthalmology · doi:10.1136/bjo.2007.116616 · Cited by 149
Vision-Related Function after Ranibizumab Treatment by Better- or Worse-Seeing Eye
Bressler, N. M., Chang, T. S., Suñer, I. J., Fine, J. T., Dolan, C., Ward, J., & Ianchulev, T. (2010) · Ophthalmology · doi:10.1016/j.ophtha.2009.09.002 · Cited by 150
“We conclude that the totality of the data favors treating these lesions with ranibizumab over PDT in the worse-seeing eye for the following reasons: (1) visual acuity outcomes are better with ranibizumab than with control for all lesion types presenting in the worse-seeing eye; (2) MARINA showed that vision-related fu…”
BackgroundGillies, M. C., Walton, R., Liong, J., Arnold, J., McAllister, I. L., Morlet, N., Hunyor, A. P., Guymer, R. H., Keeffe, J., Essex, R. W., et al. (2013) · Retina · doi:10.1097/iae.0b013e318296b271 · Cited by 155
Macular Atrophy in the HARBOR Study for Neovascular Age-Related Macular Degeneration
Sadda, S. R., Tuomi, L. L., Ding, B., Fung, A. E., & Hopkins, J. J. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2017.12.026 · Cited by 142
Tian, Y., Zhang, F., Qiu, Y., Wang, S., Li, F., Zhao, J., Pan, C., Tao, Y. K., Yu, D., & Wei, W. (2021) · Nature Biomedical Engineering · doi:10.1038/s41551-021-00764-3 · Cited by 158
Carneiro, Â. M., Costa, R., Falcão, M. S., Barthelmes, D., Mendonça, L. S., Fonseca, S. L., Gonçalves, R., Gonçalves, C., Falcão‐Reis, F. M., & Soares, R. (2012) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2011.02240.x · Cited by 147
“Nevertheless, pan-VEGF inhibition with bevacizumab or ranibizumab provides the best visual results achieved so far in the treatment of neovascular AMD (Brown et al. 2006, 2009; Rosenfeld et al. 2006).”
BackgroundHormel, T. T., Jia, Y., Jian, Y., Hwang, T. S., Bailey, S. T., Pennesi, M. E., Wilson, D. J., Morrison, J. C., & Huang, D. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100878 · Cited by 158
“Treatment of CNV with injection of intravitreal anti-vascular endothelial growth factor is highly effective in preserving vision (Brown et al., 2006).”
BackgroundPugazhendhi, A., Hubbell, M., Jairam, P., & Ambati, B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22031170 · Cited by 141
Reticular pseudodrusen: A critical phenotype in age-related macular degeneration
Wu, Z., Fletcher, E. L., Kumar, H., Greferath, U., & Guymer, R. H. (2021) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2021.101017 · Cited by 154
Keane, P. A., Liakopoulos, S., Ongchin, S. C., Heussen, F. M., Msutta, S., Chang, K. T., Walsh, A. C., & Sadda, S. R. (2008) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.08-1689 · Cited by 145
Predictors of anti-VEGF treatment response in neovascular age-related macular degeneration
Finger, R. P., Wickremasinghe, S. S., Baird, P. N., & Guymer, R. H. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2013.03.009 · Cited by 144
Bevacizumab (Avastin) for the Treatment of Ocular Disease
Gunther, J. B., & Altaweel, M. M. (2009) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2009.02.004 · Cited by 143
Framme, C., Schweizer, P., Imesch, M., Wolf, S., & Wolf-Schnurrbusch, U. E. K. (2012) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.12-9950 · Cited by 143
Aflibercept for neovascular age-related macular degeneration
Sarwar, S., Clearfield, E., Soliman, M. K., Sadiq, M. A., Baldwin, A. J., Hanout, M., Agarwal, A., Sepah, Y. J., Do, D. V., & Nguyen, Q. D. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011346.pub2 · Cited by 142
Niwa, Y., Kakinoki, M., Sawada, T., Wang, X., & Ohji, M. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-17279 · Cited by 139
Lim, J. H., Wickremasinghe, S. S., Xie, J., Chauhan, D. S., Baird, P. N., Robman, L. D., Hageman, G., & Guymer, R. H. (2012) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2011.09.013 · Cited by 141
Colquitt, J., Jones, J., Tan, S., Takeda, A., Clegg, A., & Price, A. (2008) · Health Technology Assessment · doi:10.3310/hta12160 · Cited by 140
Aflibercept (VEGF Trap-eye): the newest anti-VEGF drug
Stewart, M. W. (2012) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2011-300654 · Cited by 140
Finger, R. P., Daïen, V., Eldem, B. M., Talks, J. S., Korobelnik, J., Mitchell, P. L. R., Sakamoto, T., Wong, T. Y., Pantiri, K., & Carrasco, J. (2020) · BMC Ophthalmology · doi:10.1186/s12886-020-01554-2 · Cited by 163
Zarbin, M. A., & Rosenfeld, P. J. (2010) · Retina · doi:10.1097/iae.0b013e3181f57e30 · Cited by 140
Koizumi, H., Kano, M., Yamamoto, A., Saito, M., Maruko, I., Sekiryu, T., Okada, A. A., & Iida, T. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.10.039 · Cited by 141
Age-related Macular Degeneration: Genetic and Environmental Factors of Disease
Chen, Y., Bedell, M., & Zhang, K. (2010) · Molecular Interventions · doi:10.1124/mi.10.5.4 · Cited by 161
Anti–Vascular Endothelial Growth Factor Pharmacotherapy for Age-Related Macular Degeneration
Ip, M. S., Scott, I. U., Brown, G. C., Brown, M. M., Ho, A. C., Huang, S. S., & Recchia, F. M. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.08.012 · Cited by 142
“The Anti-VEGF Antibody for the Treatment of Predominantly Classic CNV in AMD (ANCHOR) study enrolled 423 patients with predominantly classic subfoveal CNV associated with AMD and compared ranibizumab injection with verteporfin photodynamic therapy; currently, published data are available for 12 months of treatment.(39…”
MethodResultInfluentialDetection of age-related macular degeneration via deep learning
Burlina, P., Freund, D. E., Joshi, N., Wolfson, Y., & Bressler, N. M. (2016) · 2016 IEEE 13th International Symposium on Biomedical Imaging (ISBI) · doi:10.1109/isbi.2016.7493240 · Cited by 134
“Recent clinical trials have shown that intraocular injections of anti-VEGF agents can significantly reduce the risk of vision loss when compared to no treatment, laser photocoagulation, or photodynamic therapy with verteporfin.(2-4) Furthermore, the better the visual acuity at the start of anti-VEGF treatment, the gre…”
BackgroundAflibercept in wet AMD: specific role and optimal use
Semeraro, F., Morescalchi, Duse, S., Parmeggiani, F., Gambicorti, & Costagliola, C. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s40215 · Cited by 135
Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab
Meyer, C. H., & Holz, F. G. (2011) · Eye · doi:10.1038/eye.2011.66 · Cited by 143
Lin, M., Chen, Y., Jin, J., Hu, Y., Zhou, K. K., Zhu, M., Le, Y.-Z., Ge, J., Johnson, R. S., & Ma, J.-X. (2011) · Diabetologia · doi:10.1007/s00125-011-2081-0 · Cited by 138
“More and more evidence indicates that no single growth factor acts alone to cause retinal neovascularisation [4, 33 ].”
Hoang, Q. V., Mendonça, L. S., Torre, K. E. D., Jung, J. J., Tsuang, A. J., & Freund, K. B. (2011) · Ophthalmology · doi:10.1016/j.ophtha.2011.08.011 · Cited by 140
“Also, an increase in concentration of aqueous humor protein has been associated with elevated IOP in uveitis.(1,2,18) It has been suggested that an immunologic reaction may be induced by anti-VEGF agents, resulting in inflammation and subsequent IOP elevation.”
InfluentialRanibizumab for the treatment of wet AMD: a summary of real-world studies
Chong, V (2016) · Eye · doi:10.1038/eye.2015.217 · Cited by 135
A Safety Review and Meta-Analyses of Bevacizumab and Ranibizumab: Off-Label versus Goldstandard
Schmucker, C., Ehlken, C., Agostini, H. T., Antes, G., Ruecker, G., Lelgemann, M., & Loke, Y. K. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042701 · Cited by 137
“The inclusion criteria were met by 11 RCTs [14,19–28] (19 publications [14,19–36]): three head-to-head studies [14,19,20] (three publications) with a total of 1333 patients, five RCTs [21– 25] (12 publications [21–25,29–35]) comparing ranibizumab against any other treatment or dosage with a total of 4054 patients, and…”
BackgroundCohen, S. Y., Dubois, L., Tadayoni, R., Fajnkuchen, F., Nghiem‐Buffet, S., Delahaye-Mazza, C., Guiberteau, B., & Quentel, G. (2009) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2009.04.001 · Cited by 136
Campochiaro, P. A., Avery, R., Brown, D. M., Heier, J. S., Ho, A. C., Huddleston, S. M., Jaffe, G. J., Khanani, A. M., Pakola, S., Pieramici, D. J., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)00310-6 · Cited by 135
Self-citationFeigl, B. (2008) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2008.11.004 · Cited by 149
“%) as shown in large clinical trials, when applied monthly (Brown et al., 2006; Rosenfeld et al., 2006a,b).”
BackgroundMethodInfluentialTseng, J., Vance, S. K., Torre, K. E. D., Mendonça, L. S., Cooney, M. J., Klancnik, J. M., Sorenson, J. A., & Freund, K. B. (2011) · Journal of Glaucoma · doi:10.1097/ijg.0b013e31820d7d19 · Cited by 136
VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration
Dixon, J. A., Oliver, S. C., Olson, J. L., & Mandava, N. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/13543780903201684 · Cited by 135
“Ranibizumab is the only drug in widespread use currently approved by the FDA for treatment of neovascular AMD and is by far the most extensively studied [26,27,29,30].”
BackgroundMethodInfluentialEndothelium-Microenvironment Interactions in the Developing Embryo and in the Adult
Red‐Horse, K., Crawford, Y., Shojaei, F., & Ferrara, N. (2007) · Developmental Cell · doi:10.1016/j.devcel.2007.01.013 · Cited by 141
“Anti-VEGF therapy is also beneficial in treating the wet (neovascular) form of age-related macular degeneration (Brown et al., 2006; Gragoudas et al., 2004).”
BackgroundAge-related macular degeneration: diagnosis and management
Cook, H. L., Patel, P. J., & Tufail, A. (2008) · British Medical Bulletin · doi:10.1093/bmb/ldn012 · Cited by 131
Vortex Vein Anastomosis at the Watershed in Pachychoroid Spectrum Diseases
Matsumoto, H., Hoshino, J., Mukai, R., Nakamura, K., Kikuchi, Y. S., Kishi, S., & Akiyama, H. (2020) · Ophthalmology Retina · doi:10.1016/j.oret.2020.03.024 · Cited by 133
Papadopoulou, D. N., Mendrinos, E., Mangioris, G., Donati, G., & Pournaras, C. J. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.03.017 · Cited by 133
Waldstein, S. M., Wright, J., Warburton, J., Margaron, P., Simader, C., & Schmidt-Erfurth, U. M. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2015.09.013 · Cited by 136
Peden, M. C., Suñer, I. J., Hammer, M. E., & Grizzard, W. S. (2015) · Ophthalmology · doi:10.1016/j.ophtha.2014.11.018 · Cited by 131
Brechner, R. J., Rosenfeld, P. J., Babish, J. D., & Caplan, S. (2011) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2010.11.017 · Cited by 131
Anti–Vascular Endothelial Growth Factor Agents in the Treatment of Retinal Disease
Campochiaro, P. A., Aiello, L. P., & Rosenfeld, P. J. (2016) · Ophthalmology · doi:10.1016/j.ophtha.2016.04.056 · Cited by 151
Wykoff, C. C., Ou, W. C., Brown, D. M., Croft, D. E., Wang, R., Payne, J. F., Clark, W. L., Abdelfattah, N. S., & Sadda, S. R. (2017) · Ophthalmology Retina · doi:10.1016/j.oret.2016.12.004 · Cited by 135
Self-citationFat Consumption and Its Association With Age-Related Macular Degeneration
Chong, E. W.-T. (2009) · Archives of Ophthalmology · doi:10.1001/archophthalmol.2009.60 · Cited by 132
Lai, T. Y. Y., Staurenghi, G., Lanzetta, P., Holz, F. G., Liew, S. H. M., Desset-Brèthes, S., Staines, H., Hykin, P. G., & on behalf of the MINERVA study group (2017) · Retina · doi:10.1097/iae.0000000000001744 · Cited by 140
Sahni, J., Dugel, P. U., Patel, S. S., Chittum, M. E., Berger, B., del Valle Rubido, M., Sadikhov, S., Szczesny, P., Schwab, D., Nogoceke, E., et al. (2020) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2020.2685 · Cited by 129
Seeing through VEGF: innate and adaptive immunity in pathological angiogenesis in the eye
Sene, A., Chin-Yee, D., & Apte, R. S. (2015) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2014.10.005 · Cited by 130
Gemenetzi, M. K., Lotery, A. J., & Patel, P. J. (2016) · Eye · doi:10.1038/eye.2016.208 · Cited by 145
Sustained suppression of VEGF for treatment of retinal/choroidal vascular diseases
Campochiaro, P. A., & Akhlaq, A. (2020) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2020.100921 · Cited by 132
Oxidative stress promotes ocular neovascularization
Dong, A., Xie, B., Shen, J., Yoshida, T., Yokoi, K., Hackett, S. F., & Campochiaro, P. A. (2009) · Journal of Cellular Physiology · doi:10.1002/jcp.21698 · Cited by 129
Persisent ocular hypertension following intravitreal ranibizumab
Bakri, S. J., McCannel, C. A., Edwards, A. O., & Moshfeghi, D. M. (2008) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-008-0819-2 · Cited by 129
“In the MARINA [2], and ANCHOR [ 3 ] trials, ranibizumab had no long-term effect on intraocular pressure, on average, as assessed by monthly preinjection measurements during the 2-year follow-up.”
Intravitreal Silicone Oil Droplets After Intravitreal Drug Injections
Bakri, S. J., & Ekdawi, N. S. (2008) · Retina · doi:10.1097/iae.0b013e31816c6868 · Cited by 128
Antiangiogenic Approaches to Age-Related Macular Degeneration Today
Bressler, N. M. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.06.048 · Cited by 135
Gillies, M. C., Hunyor, A. P., Arnold, J., Guymer, R. H., Wolf, S., Ng, P., Pecheur, F. L., & McAllister, I. L. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2018.6776 · Cited by 140
Motozawa, N., An, G., Takagi, S. T., Kitahata, S., Mandai, M., Hirami, Y., Yokota, H., Akïba, M., Tsujikawa, A., Takahashi, M., et al. (2019) · Ophthalmology and Therapy · doi:10.1007/s40123-019-00207-y · Cited by 137
Lazić, R., & Gabrić, N. (2007) · Ophthalmology · doi:10.1016/j.ophtha.2007.03.006 · Cited by 128
Cruess, A. F., Zlateva, G., Xu, X., Soubrane, G., Pauleikhoff, D., Lotery, A., Mones, J., Buggage, R., Schaefer, C., Knight, T., et al. (2008) · PharmacoEconomics · doi:10.2165/00019053-200826010-00006 · Cited by 126
Self-citationLyall, D. A. M., Tey, A., Foot, B., Roxburgh, S. T. D., Virdi, M., Robertson, C., & MacEwen, C. J. (2012) · Eye · doi:10.1038/eye.2012.199 · Cited by 141
Verteporfin plus Ranibizumab for Choroidal Neovascularization in Age-related Macular Degeneration
Larsen, M., Schmidt-Erfurth, U. M., Lanzetta, P., Wolf, S., Simader, C., Tokaji, E., Pilz, S., & Weisberger, A. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2012.02.002 · Cited by 128
Anti-VEGF Therapy and the Retina: An Update
Tah, V., Orlans, H. O., Hyer, J., Casswell, E., Din, N., Sri Shanmuganathan, V., Ramskold, L., & Pasu, S. (2015) · Journal of Ophthalmology · doi:10.1155/2015/627674 · Cited by 124
“ANCHOR was a 2-year, randomised, double-blind trial comparing ranibizumab with PDT in predominantly classic subfoveal CNV [11, 33].”
BackgroundMethodInfluentialAbedi, F., Wickremasinghe, S., Islam, A. F. M., Inglis, K. M., & Guymer, R. H. (2014) · Retina · doi:10.1097/iae.0000000000000134 · Cited by 124
“2) ETDRS scores in the ANCHOR study.(15)”
Thulliez, M., Angoulvant, D., Lez, M. L., Jonville‐Béra, A. ‐., Pisella, P., Gueyffier, F., & Bejan‐Angoulvant, T. (2014) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2014.2333 · Cited by 135
Wickremasinghe, S. S., Michalova, K., Gilhotra, J., Guymer, R. H., Harper, C. A., Wong, T. Y., & Qureshi, S. (2008) · Ophthalmology · doi:10.1016/j.ophtha.2008.05.007 · Cited by 124
Dadgostar, H., Ventura, A. A. C. M., Chung, J. Y., Sharma, S. K., & Kaiser, P. K. (2009) · Ophthalmology · doi:10.1016/j.ophtha.2009.05.033 · Cited by 125
Self-citationHolz, F. G., Tadayoni, R., Beatty, S., Berger, A., Cereda, M. G., Hykin, P., Staurenghi, G., Wittrup-Jensen, K., Altemark, A., Nilsson, J., et al. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-308166 · Cited by 124
Khanna, S., Komati, R., Eichenbaum, D. A., Hariprasad, I., Ciulla, T. A., & Hariprasad, S. M. (2019) · BMJ Open Ophthalmology · doi:10.1136/bmjophth-2019-000398 · Cited by 124
Guidance for anti-VEGF intravitreal injections during the COVID-19 pandemic
Korobelnik, J., Loewenstein, A., Eldem, B. M., Joussen, A. M., Koh, A., Lambrou, G. N., Lanzetta, P., Li, X., Lövestam‐Adrian, M., Navarro, R., et al. (2020) · Graefe s Archive for Clinical and Experimental Ophthalmology · doi:10.1007/s00417-020-04703-x · Cited by 124
“Fixed-dosing regimens reduce time spent in the clinic and have been shown in pivotal clinical trials to be an effective way of delivering treatment [19, 27, 28].”
BackgroundShort-term Effect of Intravitreal Injection of Ranibizumab (Lucentis) on Intraocular Pressure
Gismondi, M., Salati, C., Salvetat, M. L., Zeppieri, M., & Brusini, P. (2009) · Journal of Glaucoma · doi:10.1097/ijg.0b013e31819c4893 · Cited by 133
Ho, V. Y., Yeh, S., Olsen, T. W., Bergstrom, C. S., Yan, J., Cribbs, B. E., & Hubbard, G. B. (2013) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2013.02.009 · Cited by 122
Boulanger-Scemama, E., Querques, G., About, F., Puche, N., Srour, M., Mane, V., Massamba, N., Canoui-Poitrine, F., & Souied, E. H. (2015) · Journal Français d'Ophtalmologie · doi:10.1016/j.jfo.2014.11.015 · Cited by 124
LADAS, I. D., KARAGIANNIS, D. A., ROUVAS, A. A., KOTSOLIS, A. I., LIOTSOU, A., & VERGADOS, I. (2009) · Retina · doi:10.1097/iae.0b013e31819a5f98 · Cited by 122
Extended Release of Bevacizumab by Thermosensitive Biodegradable and Biocompatible Hydrogel
Wang, C., Hwang, Y., Chiang, P.-R., Shen, C., Hong, W.-H., & Hsiue, G. (2011) · Biomacromolecules · doi:10.1021/bm2009558 · Cited by 128
Meyer, C. H., Michels, S., Rodrigues, E. B., Hager, A., Mennel, S., Schmidt, J. C., Helb, H.-M., & Farah, M. E. (2011) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.2010.02064.x · Cited by 120
Genetic association with response to intravitreal ranibizumab in patients with neovascular AMD
Kloeckener-Gruissem, B., Barthelmes, D., Labs, S., Schindler, C., Kurz-Levin, M., Michels, S., Fleischhauer, J., Berger, W., Sutter, F., & Menghini, M. (2011) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.10-6080 · Cited by 120
Optobionic vision—a new genetically enhanced light on retinal prosthesis
Degenaar, P. A., Grossman, N., Memon, M. A., Burrone, J., Dawson, M. D., Drakakis, E. M., Neil, M. A. A., & Nikolić, K. (2009) · Journal of Neural Engineering · doi:10.1088/1741-2560/6/3/035007 · Cited by 120
“[3] and photodynamic therapies can slow progression, but”
BackgroundAntivascular endothelial growth factor therapy for neovascular age-related macular degeneration
Ciulla, T. A., & Rosenfeld, P. J. (2009) · Current Opinion in Ophthalmology · doi:10.1097/icu.0b013e32832d25b3 · Cited by 117
Age‐Related Macular Degeneration
Cheung, L. K., & Eaton, A. (2013) · Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.1264 · Cited by 120
“5 mg or photodynamic therapy (PDT) with verteporfin.(81) PDT with verteporfin was approved by the FDA in 2000 for the treatment of predominantly classic subfoveal CNV.”
MethodDaniel, E., Pan, W., Ying, G.-S., Kim, B. J., Grunwald, J. E., Ferris, F. L., Jaffe, G. J., Toth, C. A., Martin, D. F., Fine, S. L., et al. (2018) · Ophthalmology · doi:10.1016/j.ophtha.2018.01.004 · Cited by 119
Management of pseudophakic cystoid macular edema
Guo, S., Patel, S. N., Baumrind, B. R., Johnson, K. S., Levinsohn, D., Marcus, E., Tannen, B. L., Roy, M. S., Bhagat, N., & Zarbin, M. A. (2014) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2014.08.005 · Cited by 120
Fit for the Eye: Aptamers in Ocular Disorders
Drolet, D. W., Green, L. S., Gold, L., & Janjić, N. (2016) · Nucleic Acid Therapeutics · doi:10.1089/nat.2015.0573 · Cited by 130
Metadata
- Authors
- Brown, D. M., Kaiser, P. K., Michels, M., Soubrane, G., Heier, J. S., Kim, R. Y., Sy, J. P., & Schneider, S.
- Affiliations
- Houston Methodist (US)
- Cleveland Clinic (US)
- Retina Care Specialists (US)
- Ophthalmic Consultants of Boston (US)
- Genentech (US)
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2006-10-05
- Volume
- 355
- Issue
- 14
- Pages
- 1432-1444
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2085712747
- Cited by
- 3,522
- References
- 19
- Citations by year
- 2026: 97 · 2025: 110 · 2024: 115 · 2023: 97 · 2022: 117 · 2021: 189 · 2020: 178 · 2019: 140 · 2018: 154 · 2017: 170 · 2016: 188 · 2015: 209 · 2014: 218 · 2013: 247 · 2012: 257
- FWCI
- 161.74
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- BORIS (University Library Bern) (submittedVersion)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Ophthalmology › Retinal and Macular Surgery
- Health Sciences › Medicine › Ophthalmology › Ocular Diseases and Behçet’s Syndrome
- Keywords
- ranibizumab, verteporfin, neovascular age-related macular degeneration, anti-VEGF therapy, photodynamic therapy, intravitreal injection, visual acuity, endophthalmitis, uveitis
- MeSH terms
- Ranibizumab, Verteporfin, Aged, Aged, 80 and over, Antibodies, Monoclonal, Double-Blind Method, Female, Humans, Injections, Macular Degeneration, Male, Middle Aged, Photochemotherapy, Porphyrins, Visual Acuity, Photosensitizing Agents, Choroidal Neovascularization, Angiogenesis Inhibitors, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.